BiotechTube
EyeCRO

EyeCRO

Durham, United States· Est.
eyecro.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2010 and based in Durham, North Carolina, EyeCRO has established itself as a global leader in preclinical ophthalmic research services, having served over 400 companies and institutions. Its core business is providing specialized CRO services, supported by a proprietary drug delivery technology, MiDROPS®, which is protected by broad international patents. The company leverages over two decades of collective scientific expertise and AAALAC-accredited facilities to generate reproducible data for clients advancing novel therapies for anterior and posterior segment eye diseases.

Ophthalmology

Technology Platform

MiDROPS® (Microemulsion Drug Ocular Penetration System) - a proprietary microemulsion platform for formulating lipophilic small molecules into eyedrops, enabling delivery to both anterior and posterior segments of the eye.

Funding History

1
Series AUndisclosed

Opportunities

The growing global ophthalmic R&D market and the trend toward outsourcing preclinical work provide a strong tailwind for its CRO services.
The MiDROPS® platform addresses a major formulation challenge, offering a significant opportunity to out-license the technology for numerous lipophilic compounds, potentially converting injectable therapies into non-invasive eyedrops.

Risk Factors

Revenue is dependent on the cyclical R&D spending of biopharma clients, which can contract during economic downturns.
The commercial success of the MiDROPS® platform relies on securing adoption and licensing partnerships against competing drug delivery technologies.
As a specialized service provider, it may face concentration risk if reliant on a few large clients.

Competitive Landscape

EyeCRO competes with other preclinical CROs offering ophthalmology services, such as Charles River Laboratories' ophthalmology segment, InVivo Biosystems, and smaller specialized labs. Its MiDROPS® platform competes in the drug delivery space with technologies from companies like Ocular Therapeutix, Santen, and various academic spin-offs developing nanoemulsions and other novel formulations.

More companies in Diagnostics & Precision Medicine →More companies in United States →